Publications in collaboration with researchers from University of Tübingen (27)

2024

  1. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis

    Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804

  2. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Blood cancer journal

  3. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Clinical Cancer Research, Vol. 29, Núm. 12, pp. 2250-2265

  4. Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411)

    Cancers, Vol. 15, Núm. 4

  5. Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna

    Annals of Oncology

  6. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

    Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77

2022

  1. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

    Clinical Cancer Research, Vol. 28, Núm. 12, pp. 2555-2566

  2. Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT

    Clinical Colorectal Cancer, Vol. 21, Núm. 4, pp. 285-296

  3. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort

    Neuro-oncology, Vol. 24, Núm. 10, pp. 1726-1735

  4. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Publisher Correction: A community-based transcriptomics classification and nomenclature of neocortical cell types (Nature Neuroscience, (2020), 23, 12, (1456-1468), 10.1038/s41593-020-0685-8)

    Nature Neuroscience

  3. The ESSO core curriculum committee update on surgical oncology

    European Journal of Surgical Oncology, Vol. 47, Núm. 11, pp. e1-e30

2019

  1. Corrigendum to “New vaccination strategies in liver cancer” [Cytokine Growth Factor Rev. 36 (2017) 125–129](S1359610117301089)(10.1016/j.cytogfr.2017.06.010)

    Cytokine and Growth Factor Reviews

  2. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma

    Genome Medicine, Vol. 11, Núm. 1

  3. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 253-264

2018

  1. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  2. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017